key: cord-1039731-yvm2qs16
authors: Ware, Lorraine B
title: Physiological and biological heterogeneity in COVID-19-associated acute respiratory distress syndrome
date: 2020-08-27
journal: Lancet Respir Med
DOI: 10.1016/s2213-2600(20)30369-6
sha: 0b9e60da764f805dea7c4086225868ef647cced7
doc_id: 1039731
cord_uid: yvm2qs16

nan

One of the most common causes of hospital admission and death in patients with severe acute respiratory syndrome coronavirus 2 (SARSCoV2) infection is acute respiratory distress syndrome (ARDS), a clinical syndrome characterised by acute lung inflammation and increasedpermeability pulmonary oedema due to injury to the alveolar capillary barrier. As clinicians care for a surge of patients with ARDS due to COVID19, two questions arise. First, is COVID19associated ARDS intrinsically different from ARDS unrelated to COVID19?

The answer to this question has implications for the use of evidencebased therapies such as lungprotective mechanical ventilation, proning, and conservative fluid management in COVID19associated ARDS. ARDS, and the extent of pulmonary oedema in patients with COVID19, measured by calculation of total lung weights from lung CT scans, was similar to that of patients with classical ARDS. Ddimers in 261 patients with COVID19 were associated with ventilatory ratio, which is a surrogate for deadspace ventilation. A subgroup of patients with Ddimer concentrations greater than the median and static compliance equal to or less than the median (high Ddimers, low compliance [HDLC]) had markedly worse 28day mortality than the others subgroups of high Ddimers, high compliance (HDHC); low Ddimers, low compliance (LDLC); and low Ddimers, high compliance (LDHC). 28day mortality was 56% (40 of 71 patients) in the HDLC group, 27% (18 of 67 patients) in the LDHC group, 22% (13 of 60 patients) in the LDLC group, and 35% (22 of 63 patients) in the HDHC group. This worse survival in the HDLC group suggests that the intersection of more severe dysregulation of coagulation and fibrinolysis with more severe lung injury in COVID19associated ARDS is highly deleterious, supporting a pathophysiological role for pulmonary microvascular thrombosis in COVID19associated ARDS, as has been reported in classical ARDS. Overall, the findings of this large, systematic, multicentre study provide new evidence that lung physiology in COVID19associated ARDS is heterogeneous and not fundamentally different from that of classical ARDS, in contrast to previous singlecentre reports in small groups of patients that suggested otherwise. 5 As such, these findings support recent calls for the application of evidencebased ARDS care, such as lungprotective mechanical ventilation and proning, in COVID19associated ARDS. 6 The Article from Pratik Sinha and colleagues 7 addresses the question of whether the previously described hyperinflammatory and hypoinflammatory phenotypes of classical ARDS are present in COVID19 associated ARDS. Validated models for phenotype classification 8 were applied to 39 patients with COVID19associated ARDS, using pointofcare biomarker measurements at the bedside. Patients could be classified into the two phenotypes with a high degree of certainty, suggesting that the previously identified ARDS phenotypes are robust in this new patient population. Overall mortality in COVID19 associated ARDS was higher (17 [44%] of 39 patients had died by day 28 of the study) than in a matched cohort of patients with classical ARDS from the HARP2 study (132 [24%] of 539). Consistent with classical ARDS, mortality in the hyperinflammatory phenotype (five [63%] of eight patients) was substantially higher than in the hypoinflammatory phenotype (12 [39%] of 31). Yet, in COVID19associated ARDS, only four (10%) to eight (21%), depending on cutoffs applied, were classified as hyperinflammatory, which was considerably lower than the proportion with this phenotype in the HARP2 matched cohort (186 [35%] of 539). These findings are surprising, given the prevalent speculation in the literature that severe COVID19 is characterised by an excessive inflammatory response or socalled cytokine storm. However, a report comparing interleukin6 (IL6) levels in patients with COVID19associated ARDS to levels measured in classical ARDS showed that IL6 levels, on average, were lower in the patients with COVID19 than in those with classical ARDS. 9 Taken together, these findings suggest that the pathophysiology of COVID19associated ARDS is more complex than a simple overproduction of cytokines, and that there is heterogeneity within COVID19 that is similar to that of classical ARDS, albeit with different distributions.

Although both of these studies provide new information about COVID19associated ARDS, there are some limitations. The study by Grasselli and colleagues 4 was done over a 2week period during a rapid spike in COVID19 cases, which might have affected clinical care; and it reflects cases in only one country. The study by Sinha and colleagues 7 is also geographically limited and had a very small sample size. Both studies assessed patients at a single timepoint, which might not be reflective of the protracted course of critical illness in many patients with COVID 19associated ARDS. A report of deep immune profiling of patients with COVID19 identified three immunophenotypes that were quite stable over 7 days, but some immunological signatures that were highly dynamic over time, underscoring the need for serial analyses. 10 Despite the limitations, the authors of both of these studies are to be commended for applying highquality research methods during a surge of COVID19 cases.

The ongoing COVID19 pandemic reminds physicians daily of the importance of clinical investigation as a tool for improving the understanding and treatment of human disease. Like all good clinical investigations, the studies from Grasselli and colleagues 4 and Sinha and colleagues 7 provide answers that lead to new questions. The study by Grasselli and colleagues 4 prompts the question of whether identification of an HDLC group could be used to predictively enrich trials of empirical therapeutic anticoagulation to reduce sample size and improve the ratio of benefit to risk. The fact that only a small minority of the patients in the study by Sinha and colleagues 7 had a hyperinflammatory phenotype raises the question of whether dexamethasone treatment, which has been shown to be effective in patients with severe COVID19 disease, will be uniformly beneficial across both phenotypes of COVID19associated ARDS. To answer these questions and the many others that arise during the daily care of patients with COVID19 associated ARDS, it is imperative that highquality clinical investigation proceeds, despite the inherent challenges of implementing research protocols in the uncertain and risky environment of a pandemic. I The first recorded autopsy was that of Julius Caesar in 44 BCE to establish which knife wound had caused his death; the wound that ruptured his aorta was the culprit. Autopsies have been the foundation of medical advancement over the subsequent centuries, and were done in 40-60% of all hospital deaths as recently as the 1950s. 1,2 With increasingly sophisticated imaging and diagnostic advancements, autopsy rates have declined substantially to less than 1%. 3 Despite these advancements, clinically missed diagnoses involving a primary cause of death are found at autopsy about 8-24% of the time. 4 Given the frequency of misclassification when clinicians diagnose familiar diseases; ecigarette, or vaping, product useassociated lung injury (EVALI), a new syndrome whose definition is evolving, is expected to result in similar or even greater diagnostic error. Initial reports were based on a nonspecific clinical case definition of vaping, imaging opacities, and exclusion of alternative explanatory diagnoses. 5 In The Lancet Respiratory Medicine, Sarah Reagan Steiner and colleagues 6 present the first systematic characterisation of EVALI using autopsy and lung biopsy findings, which help to improve the understanding of what EVALI is, and is not. In addition to lung biopsy samples from 10 patients, the report includes autopsy findings from 13 individuals, representing a quarter of patients who were reported to have died from EVALI (52 as of Dec 10, 2019). 7 Three (23%) of 13 individuals who died from suspected EVALI had pulmonary pathology suggesting an alternative or concomitant disease. In retrospect, given the pathological findings of bronchopneumonia, bronchoaspiration, or interstitial lung disease, these patients would not have met the definition of EVALI that required exclusion of alternative diagnoses. Clinicians face this diagnostic challenge daily, with inadequate data, and they need to decide how invasive an evaluation should be to exclude alternative causes of respiratory failure.

The findings generated from this pathological case series reveal how heterogenous a lethal syndrome such as EVALI can be. Severe diseases often manifest with multiple organ dysfunction regardless of the original injury. Some patients with EVALI had microthrombi in the renal glomeruli, and other studies have characterised patients with gastrointestinal symptoms. 5, 8 Additionally, the presence of fibrosis, aspiration, infection, heart failure, and asthma all suggest alternative or additional diagnoses in up to 

Pathophysiology of COVID19 associated acute respiratory distress syndrome: a multicentre prospective observational study

COVID19 does not lead to a "typical" acute respiratory distress syndrome

COVID19associated acute respiratory distress syndrome: is a different approach to management warranted?

Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID19: a prospective observational study

Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials

Is a "cytokine storm" relevant to COVID19?

Deep immune profiling of COVID19 patients reveals distinct immunotypes with therapeutic implications